Onconova Announces Presentations Related To Rigosertib Clinical Studies In Myelodysplastic Syndromes At The 2016 ASH Annual Meeting

--Rigosertib plus Azacitidine Combination Phase 2 Trial Results Featured--

NEWTOWN, Pa., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that three abstracts relating to the Company's lead product candidate, rigosertib were accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting in San Diego, California, which takes place December 3-6, 2016.

Details for the presentations are listed below.

Combination Therapy Phase 2 Data Abstract Number: 3167 Title: Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study Session Name: 637. Myelodysplastic Syndromes - Clinical Studies: Poster II Date: Sunday, December 4, 2016 Presentation Time: 6:00 - 8:00 PM PST Location: Hall GH (San Diego Convention Center) Presenter: Shyamala C. Navada, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Safety Analysis Summary for >500 Patients Treated with Rigosertib in Clinical Trials Abstract Number: 2011 Title: Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Session Name: 637. Myelodysplastic Syndromes - Clinical Studies: Poster I Date: Saturday, December 3, 2016 Presentation Time: 5:30 - 7:30 PM PST Location: Hall GH (San Diego Convention Center) Presenter: Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Computational Analysis of Subgroup Data from Previous Clinical Trials Abstract Number: 4324 Title: Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response Session Name: 637. Myelodysplastic Syndromes - Clinical Studies: Poster III Date: Monday, December 5, 2016 Presentation Time: 6:00 - 8:00 PM PST Location: Hall GH (San Diego Convention Center) Presenter: Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. The Company's most advanced product candidate, rigosertib, is a small molecule inhibitor of cellular signaling and acts as a RAS mimetic. These effects of rigosertib appear to be mediated by direct binding of the compound to the RAS-binding domain (RBD) found in many RAS effector proteins, including the Raf and PI3 kinases. Rigosertib is protected by issued patents (earliest expiry in 2026) and has been awarded Orphan Designation for MDS in the United States, Europe and Japan.  In addition to rigosertib, two other candidates are in the clinical stage, and several candidates are in pre-clinical stages.  For more information, please visit  http://www.onconova.com.

About Oral Rigosertib

The oral form of rigosertib provides a more convenient dosing for use where the duration of treatment may extend to multiple years. To date, more than 350 patients have been treated with the oral formulation of rigosertib, either as a single agent or in combination with other drugs.  Phase 1 studies with oral rigosertib were conducted in hematological malignancies, lower-risk MDS and solid tumors. Combination therapy of oral rigosertib with azacitidine and chemoradiotherapy has also been explored.

If you liked this article you might like

5 Stocks Under $10 That Could Rocket Higher Soon

These 5 Stocks Under $10 Could Get Hot Soon

5 Breakout Stocks Under $10 Set to Soar

7 Stocks Under $10 Making Big Up Moves

6 Stocks Under $10 Making Big Moves Higher